Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

This study tests a new treatment sequence for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) — a fast-growing blood cancer that has come back or stopped responding to treatment. The approach uses tafasitamab (an antibody drug) with lenalidomide (an immune-modulating drug) followed by intensive chemotherapy and potentially a stem cell transplant, aiming to put the cancer into deep remission before transplant. **You may be eligible if...** - You are 18 or older - You have DLBCL that has relapsed or not responded to at least one prior treatment including an anti-CD20 antibody (such as rituximab) and chemotherapy - You are considered eligible for a stem cell transplant by your doctor - You have measurable disease on a CT or PET scan - Your overall health is acceptable (ECOG 0–2) **You may NOT be eligible if...** - You have received more than one prior line of therapy - You have active central nervous system lymphoma - You are pregnant or breastfeeding - You have serious heart, liver, or kidney conditions Talk to your doctor to see if this trial is right for you.